^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EFNB2 expression

    i
    Other names: EFNB2, Ephrin B2, HTK Ligand, Ephrin-B2, LERK5, HTKL, Eph-Related Receptor Tyrosine Kinase Ligand 5, Ligand Of Eph-Related Kinase 5, EPLG5, Htk-L, EPH-Related Receptor Tyrosine Kinase Ligand 5, MGC126226, MGC126227, MGC126228, LERK-5, EFNB2, HTK-L
    Entrez ID:
    1948
    Related biomarkers:
    Expression
    2ms
    Heterogeneous Kinetics of Nanobubble Ultrasound Contrast Agent and Angiogenic Signaling in Head and Neck Cancer. (PubMed, bioRxiv)
    We show that ephrinB2 expression by endothelial cells and EphB4 expression by cancer cells have similar effects on tumor vasculature, despite sometimes opposite effects on tumor growth. This implicates a cancer-cell-intrinsic effect of EphB4 forward signaling and not angiogenesis in EphB4's action as a tumor suppressor.
    Journal
    |
    EPHB4 (EPH receptor B4)
    |
    EFNB2 expression • EPHB4 expression
    3ms
    Circadian system disorder induced by aberrantly activated EFNB2-EPHB2 axis leads to facilitated liver metastasis in gastric cancer. (PubMed, Cell Oncol (Dordr))
    Overall, we aim to uncover the mechanism in TAMs induced CRD which promotes liver metastasis of GC and provide novel ideas for therapeutic strategies.
    Journal
    |
    EFNB2 (Ephrin B2) • EPHB2 (EPH Receptor B2)
    |
    EFNB2 expression • EPHB2 expression
    |
    clodronate disodium
    9ms
    Circular RNA circEfnb2 promotes cell injury after cerebral infarction by sponging miR-202-5p and regulating TRAF3 expression. (PubMed, Transpl Immunol)
    Our results suggest that circEfnb2 deficiency may decrease OGD/R-induced HT22 cell damage by modulating the miR-202-5p/TRAF3 axis. This explanation may provide a new direction for cerebral infarction potential therapeutic targets.
    Journal • IO biomarker • Circular RNA
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • EFNB2 (Ephrin B2) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
    |
    EFNB2 expression
    11ms
    Inhibition of Ephrin B2 Reverse Signaling Suppresses Multiple Myeloma Pathogenesis. (PubMed, Cancer Res)
    Complementary analysis of MM patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls MM pathogenesis and can be therapeutically targeted to improve MM outcomes.
    Journal
    |
    EFNB2 (Ephrin B2) • EPHB4 (EPH receptor B4) • EPHB1 (EPH Receptor B1) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    EFNB2 expression
    over1year
    Theranostic Potential of EFNB2 for Cetuximab Resistance in Head and Neck Cancer. (PubMed, Indian J Otolaryngol Head Neck Surg)
    Thus, EFNB2 has potential to be theranostic marker for CTX resistance. The online version contains supplementary material available at 10.1007/s12070-023-03739-9.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • EFNB2 (Ephrin B2) • IL1A (Interleukin 1, alpha) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    |
    EGFR expression • EFNB2 negative • EFNB2 expression
    |
    Erbitux (cetuximab)
    over1year
    EphrinB2: Expression of a novel potential target in renal cell carcinoma. (PubMed, Indian J Urol)
    EphrinB2 is expressed in approximately half of RCC cases. EphrinB2 expression in the early stage cancer might indicate its induction as an early event.
    Journal
    |
    EPHB4 (EPH receptor B4)
    |
    EFNB2 positive • EFNB2 expression
    2years
    Divergent Roles of Ephrin-B2/EphB4 Guidance System in Pulmonary Hypertension. (PubMed, Hypertension)
    In sum, pulmonary vascular remodeling was dependent on ephrin-B2-induced Eph receptor (erythropoietin-producing hepatocellular carcinoma receptor) forward signaling in SMC, while EphB4 receptor activity was necessary for RhoA expression in SMC, interaction with endothelial cells and vasoconstrictive components of pulmonary hypertension.
    Journal
    |
    RHOA (Ras homolog family member A) • EPHB4 (EPH receptor B4)
    |
    EFNB2 expression • EPHB4 expression • RHOA mutation
    2years
    Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake. (PubMed, Oncogene)
    Inhibition of the EFNB2/EPHB4 axis markedly prolonged the survival time of BALB/c nude mice with CRC LM with a high cholesterol diet. These findings revealed a key step in the regulation of cholesterol uptake by EFNB2/EPHB4 axis and its tumor-promoting role in CRC LM.
    Journal
    |
    EFNB2 (Ephrin B2) • EPHB4 (EPH receptor B4)
    |
    EFNB2 expression
    over2years
    Precision Oncology for Urinary Bladder Carcinoma With Variant Histology: Immunohistochemical Expression of TROP2 and Ephrin B2 (CAP 2022)
    Phase II clinical trials using TROP2-directed antibody-drug conjugates and a combination of pembrolizumab with sEphB4-HAS, a decoy receptor for ephrin B2, are ongoing for urothelial carcinoma... Expression of TROP2 and ephrin B2 in BCVH potentially expands the therapeutic possibilities for these patients with limited treatment options. Clinical trials to investigate the efficacy of these novel treatments on BCVH is warranted. M.A.
    PD(L)-1 Biomarker
    |
    EFNB2 (Ephrin B2)
    |
    TROP2 expression • EFNB2 expression
    |
    Keytruda (pembrolizumab)
    over2years
    Precision Oncology for Urinary Bladder Carcinoma With Variant Histology: Immunohistochemical Expression of TROP2 and Ephrin B2 (CAP 2022)
    Phase II clinical trials using TROP2-directed antibody-drug conjugates and a combination of pembrolizumab with sEphB4-HAS, a decoy receptor for ephrin B2, are ongoing for urothelial carcinoma... Expression of TROP2 and ephrin B2 in BCVH potentially expands the therapeutic possibilities for these patients with limited treatment options. Clinical trials to investigate the efficacy of these novel treatments on BCVH is warranted. M.A.
    PD(L)-1 Biomarker
    |
    EFNB2 (Ephrin B2)
    |
    TROP2 expression • EFNB2 expression
    |
    Keytruda (pembrolizumab)